SCHEMBL5137549

SCHEMBL5137549

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(Cc1ccccc1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 2/20 0.39
TSHR P16473 2/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
F2R P25116 2/20 0.37
ALDH1A1 P00352 4/20 0.37
NPSR1 Q6W5P4 2/20 0.37
RAB9A P51151 1/20 0.37
HIF1A Q16665 1/20 0.37
TAS2R14 Q9NYV8 1/20 0.36
GBA1 P04062 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650881 0.98 C5AR1 (0.58) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL5137636 0.94 C5AR1 (0.56) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL652765 0.92 C5AR1 (0.51) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL1913037 0.92 C5AR1 (0.52) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL1913038 0.91 C5AR1 (0.50) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL1912763 0.89 C5AR1 (0.58) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL5134563 0.87 C5AR1 (0.60) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL4763555 0.84 C5AR1 (0.67) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL5134627 0.84 C5AR1 (0.55) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1
SCHEMBL14415577 0.84 C5AR1 (0.52) C5AR1SMN1; SMN2LMNAL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed